Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty
- Author:
Kyu Hyun PARK
1
;
Si-Hwa GWAG
;
Yu Jin KIM
;
Lindsey Yoojin CHUNG
;
Eungu KANG
;
Hyo-Kyoung NAM
;
Young-Jun RHIE
;
Kee-Hyoung LEE
Author Information
- Publication Type:Original Article
- From:Annals of Pediatric Endocrinology & Metabolism 2024;29(3):161-166
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Purpose:Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.
Methods:In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.
Results:Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; p=0.875).
Conclusion:A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.
